On October 31, ARK Genomic Revolution ETF fell 8.04% in Regular Trading, with shares trading at $50.6967 and turnover reaching $428 million.
A recent catalyst tied to the move is ARK Invest's disclosed reduction in Tempus AI, a healthcare AI holding, which coincided with cautious trading sentiment toward AI-bio and genomics names.
ARK disclosed on October 30 that it sold 7,625 shares of Tempus AI on October 29, worth about $0.58 million, while using the same session to add to Cerebras Systems for a second straight day. Tempus AI had recently reported constructive business updates, including EU certification for its xR RNA sequencing assay, a multi-year $55 million collaboration linked to neurological drug research, and an expanded oncology collaboration involving Moderna and Merck. Even so, the latest market commentary indicates ARKG came under pressure as investors remained cautious on AI-medical exposure despite those developments.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
Comments